港股四季度怎么投？基金经理这样说

Group 1 - The core viewpoint of the articles is that the Hong Kong stock market is expected to benefit from the new round of interest rate cuts initiated by the Federal Reserve, leading to increased foreign investment in Chinese assets, particularly in Hong Kong stocks [1][2]. - Several public funds have reached a consensus to increase their allocation to Hong Kong stocks, indicating a significant enhancement in the willingness of external funds to flow into the Hong Kong market [1][2]. - The Hong Kong stock market has seen a strong performance this year, driven by valuation recovery, confidence restoration, and a shift in global monetary policy [2][4]. Group 2 - The recovery in valuations is attributed to improved earnings from major internet companies, which have exceeded expectations since last year's third-quarter reports [2]. - Global monetary policy changes, particularly the Federal Reserve's new interest rate cut cycle, are expected to favor emerging markets, including Hong Kong stocks [2]. - The influx of capital into the Hong Kong market is supported by increasing demand from mainland investors for undervalued assets [2][4]. Group 3 - The Hang Seng Technology Index has been highlighted as a key area of interest, with fund managers noting its long-term potential despite recent volatility due to increased competition and external uncertainties [4][5]. - The distinction between Hong Kong and A-share technology sectors is emphasized, with Hong Kong focusing more on AI applications and software, which may attract investor interest as the market shifts [4][5]. - The valuation of the Hang Seng Technology Index is currently at a relatively low level, providing a favorable investment opportunity [5]. Group 4 - New consumption sectors, such as trendy toys, new tea drinks, and beauty products, are expected to maintain high growth rates and remain attractive to investors [6]. - The innovative pharmaceutical sector is also a focus, with expectations of improved financing activities due to interest rate cuts, potentially leading to a turning point for the CXO sector [6][7]. - Despite recent volatility in the innovative drug market, confidence remains high among fund managers regarding the long-term prospects of quality pharmaceutical companies [7].